Scholar Rock
Scholar Rock reported revenue of $0 million in fiscal 2025. Free cash flow was −$301 million. The diluted share count rose 14.9%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Scholar Rock does
Scholar Rock is a biotechnology company developing antibody drugs for spinal muscular atrophy (SMA) and other rare muscle-wasting diseases. It has no approved product yet and no product sales. It says 2026 could be the year it becomes a commercial-stage company, if regulators approve its lead drug.
Its technology targets growth factors in the TGF-beta family, a group of signaling proteins. Its drugs bind the inactive forms of these proteins in muscle. The lead candidate, apitegromab, blocks myostatin, a protein that limits muscle growth, in the hope of building muscle mass and strength. The company reported positive results from a late-stage trial in children and adults with SMA in October 2024 and says it expects regulatory decisions in the United States and Europe in 2026.
The company also plans a mid-stage study of apitegromab in facioscapulohumeral muscular dystrophy (FSHD) and is developing a version given as an injection under the skin, rather than through a vein. A second candidate, SRK-439, is also an antibody that targets myostatin. Because it has no sales, the company relies on money it raises to pay for its work.
Its biggest risks, as it describes them
- Its lead drug may not be approved, or may be approved only with limits on how it can be used.
- Even if approved, apitegromab may not win acceptance from doctors, patients and insurers.
- Its clinical development depends on the continued availability of other companies' approved drug therapies.
- Results from early trials may not predict later ones, and early data it announces may change.
- Delays in enrolling patients could slow its trials and raise its costs.
Income statement
Scholar Rock lost money in fiscal 2025: a net loss of $378 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 253 | 315 | 280 | 437 | 368 |
| Debt incl. finance leases | 54 | 51 | 52 | 50 | 100 |
| Net debt (negative means net cash) | −199 | −264 | −228 | −387 | −268 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | 0.2x | 0.2x | 0.1x | 0.4x |
| Interest coverage | −61.9x | −28.6x | −26.4x | −36.9x | −55.8x |
| Current ratio | 4.1x | 9.0x | 8.8x | 9.6x | 7.0x |
| Quick ratio | 4.1x | 9.0x | 8.8x | 9.6x | 7.0x |
Cash flow
Projections
Project Scholar Rock's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Scholar Rock shares on the open market, and 13 insiders sold $19.4 million, $8.8 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | Katie PengDirector | Sold plan | 5,446 | $53.87 | $293,399 | Form 4 |
| Jul 1, 2026 | Jeffrey S. FlierDirector | Sold plan | 3,053 | $53.88 | $164,491 | Form 4 |
| Jul 1, 2026 | Joshua ReedDirector | Sold plan | 3,053 | $53.74 | $164,075 | Form 4 |
| Jul 1, 2026 | Kristina BurowDirector | Sold plan | 3,053 | $53.74 | $164,054 | Form 4 |
| Jul 1, 2026 | Michael GilmanDirector | Sold plan | 2,544 | $53.87 | $137,057 | Form 4 |
| Apr 16, 2026 | David HallalChief Executive Officer, Director | Sold | 30,615 | $49.57 | $1.5 million | Form 4 |
| Apr 16, 2026 | Akshay VaishnawPresident of R&D, Director | Sold | 12,246 | $49.57 | $607,034 | Form 4 |
| Apr 16, 2026 | Vikas SinhaChief Financial Officer | Sold | 10,410 | $49.57 | $516,024 | Form 4 |
| Apr 16, 2026 | Keith WoodsChief Operating Officer | Sold | 10,220 | $49.57 | $506,605 | Form 4 |
| Feb 23, 2026 | Mo QatananiChief Scientific Officer | Sold plan | 8,484 | $47.07 | $399,335 | Form 4 |
| Feb 17, 2026 | Junlin HoGeneral Counsel | Sold | 9,580 | $46.53 | $445,757 | Form 4 |
| Feb 17, 2026 | Caryn ParlavecchioCHRO | Sold | 9,035 | $46.53 | $420,399 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −2.65 | −0.68 | −9.91 |
| Accruals ratio | −6.2% | −11.5% | −17.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — | — | — |
Compare
Put Scholar Rock side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Scholar Rock | FY25 | — | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Arbutus Biopharma | FY25 | 128.2% | −271.0% | −281.4% | — | — | 3 | Compare |
| ADMA Biologics | FY25 | 19.6% | 37.5% | 5.5% | 39.5% | −0.1x | 5 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | 0 | 20 | 15 | 19 | 33 | — | — | 0 |
| Revenue growth | — | — | — | −24.8% | 22.2% | 76.4% | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 20 | 36 | 54 | 74 | 108 | 124 | 122 | 184 | 208 |
| Operating income | −25 | −51 | −54 | −87 | −130 | −134 | −171 | −252 | −385 |
| Net income | −25 | −49 | −51 | −86 | −132 | −134 | −166 | −246 | −378 |
| Diluted EPS (US$) | −15.30 | −3.15 | −1.85 | −2.81 | −3.59 | −2.26 | −1.99 | −2.47 | −3.29 |
| Diluted shares (millions) | 2 | 16 | 28 | 31 | 37 | 60 | 83 | 100 | 115 |
| Cash flow | |||||||||
| Cash from operations | −22 | 25 | −63 | −60 | −127 | −133 | −145 | −201 | −300 |
| Capital expenditure | 0 | 2 | 3 | 4 | 5 | 1 | 0 | 0 | 1 |
| Free cash flow | −22 | 23 | −66 | −64 | −132 | −134 | −145 | −201 | −301 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 5 | 8 | 11 | 23 | 28 | 27 | 37 | 76 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 58 | 176 | 157 | 341 | 253 | 315 | 280 | 437 | 368 |
| Debt incl. finance leases | 1 | 0 | — | 26 | 54 | 51 | 52 | 50 | 100 |
| Total assets | 62 | 181 | 196 | 388 | 304 | 358 | 311 | 475 | 404 |
| Total liabilities | 6 | 75 | 84 | 128 | 132 | 98 | 86 | 106 | 159 |
| Shareholders' equity | −54 | 107 | 113 | 261 | 172 | 260 | 225 | 369 | 246 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | −266.2% | −564.0% | −690.5% | −404.8% | — | — | — |
| Net margin | — | — | −248.9% | −561.5% | −700.5% | −405.2% | — | — | — |
| Free cash flow margin | — | — | −323.2% | −417.8% | −701.7% | −403.0% | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | −442.7% | −679.6% | −326.6% | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −185.8% | −46.5% | −46.3% | −60.9% | −62.2% | −68.3% | −83.0% | −123.1% |
| Return on assets | — | −40.6% | −27.0% | −29.6% | −38.0% | −40.6% | −49.5% | −62.7% | −86.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |